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Abstract
Background: There is currently no licensed antiviral drug for treatment of dengue. Chloroquine (CQ) inhibits the replication
of dengue virus (DENV) in vitro.
Methods and Findings: A double-blind, randomized, placebo-controlled trial of CQ in 307 adults hospitalized for suspected
DENV infection was conducted at the Hospital for Tropical Diseases (Ho Chi Minh City, Vietnam) between May 2007 and July
2008. Patients with illness histories of 72 hours or less were randomized to a 3-day course of CQ (n=153) or placebo
(n=154). Laboratory-confirmation of DENV infection was made in 257 (84%) patients. The primary endpoints were time to
resolution of DENV viraemia and time to resolution of DENV NS1 antigenaemia. In patients treated with CQ there was a
trend toward a longer duration of DENV viraemia (hazard ratio (HR)=0.80, 95% CI 0.62–1.05), but we did not find any
difference for the time to resolution of NS1 antigenaemia (HR=1.07, 95% CI 0.76–1.51). Interestingly, CQ was associated
with a significant reduction in fever clearance time in the intention-to-treat population (HR=1.37, 95% CI 1.08–1.74) but not
in the per-protocol population. There was also a trend towards a lower incidence of dengue hemorrhagic fever (odds
ratio=0.60, PP 95% CI 0.34–1.04) in patients treated with CQ. Differences in levels of T cell activation or pro- or anti-
inflammatory plasma cytokine concentrations between CQ- and placebo-treated patients did not explain the trend towards
less dengue hemorrhagic fever in the CQ arm. CQ was associated with significantly more adverse events, primarily vomiting.
Conclusions: CQ does not reduce the durations of viraemia and NS1 antigenaemia in dengue patients. Further trials, with
appropriate endpoints, would be required to determine if CQ treatment has any clinical benefit in dengue.
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Introduction
Dengue is a globally important public health problem. This
mosquito-borne viral infection results in an estimated 50 million
cases of symptomatic illness each year in over 100 affected
countries [1]. There are no licensed vaccines to prevent dengue
and no specific therapies to stop or limit viral replication or
modulate the severity of symptoms in patients.
Infection with any of the four dengue virus serotypes can cause
clinically apparent disease. A measurable viraemia is typically
present for the duration of the febrile period, with the first 48–
72hrs characterized by relatively high viraemia levels that then
rapidly decline as acquired humoral and cellular immune
responses resolve infection [2]. NS1, a non-structural protein
secreted by virus-infected cells, can be detected in the peripheral
blood in some, but not all, symptomatic individuals [3,4]. Both
viraemia and NS1 levels are higher in patients with more severe
clinical patterns of disease [5]. The majority of symptomatic
infections manifest as an acute systemic febrile illness that is
clinically uncomplicated and lasts for 3–7 days. For reasons not
fully elucidated, some DENV infections result in severe dengue, a
syndrome usually characterized by transiently increased capillary
permeability and a hemorrhagic diathesis. Parenteral fluids are
used to replenish the intravascular volume and maintain
cardiovascular stability during the period of maximum capillary
permeability. Mortality in severe dengue can be reduced to less
than 1% in experienced settings.
Previous randomized controlled trials in dengue have focused
on supportive management and to our knowledge, there has never
been a trial directed towards reducing the virus burden.
Chloroquine (CQ) is a cheap, widely available and well-tolerated
lysosomotropic 4-amino-quinoline derivative. In vitro, CQ has
modest anti-viral effects on replication of viruses from diverse
taxonomic families (reviewed in [6]). This has led to speculation
that CQ could have a therapeutic role in the treatment of viral
diseases where there are limited or no other therapies [6,7]. In the
context of DENV, the lysosomotropic and weak base properties of
CQ could exert anti-viral activity by interfering with endosomal
www.plosntds.org 1 August 2010 | Volume 4 | Issue 8 | e785fusion and furin-dependent virus maturation, which both require
low pH environments in late endosomes and the lumen of the
trans-Golgi network respectively [8,9]. Indeed, treatment of
mammalian-expressing cells with chloroquine inhibits DENV
infection [10]. Furthermore, treatment of DENV-2 infected
mammalian cells with chloroquine reduces the infectivity of the
produced virus by six- to eightfold, possibly by reducing the
efficiency of the virus maturation process [11]. The 50% inhibitory
concentration of chloroquine for DENV [10] is achievable inside
human cells following ingestion of standard doses of CQ [12,13].
CQ could also modulate the host response to virus infection.
Recognition of viral products by plasmacytoid dendritic cells
(pDCs) occurs through a TLR-dependent pathway that requires
endosomes acidification [14,15]; chloroquine-mediated blocking
of this process partially inhibited West Nile virus-induced IFN-a
production by pDC cultures [16]. CQ could also modulate antigen
processing via an increased export of soluble antigens into the
cytosol of DCs [17]. CQ also attenuates inflammatory cytokine
responses [18,19] and this may in part explain why CQ is used
as a 2
nd line therapy in the treatment of inflammatory disorders
such as rheumatoid arthritis and systemic lupus erythematosus
[20,21,22,23]. Possibly related to its anti-inflammatory properties,
CQ exerts an antipyretic effect equal to paracetamol during
treatment of uncomplicated P. falciparum malaria [24].
Against a backdrop of interest in CQ as a therapeutic for acute
viral infections [6,7], the purpose of this study was to evaluate CQ
Author Summary
There is no available drug or vaccine against dengue, an
acute viral disease that affects ,50 million people annually
in tropical and sub-tropical countries. Chloroquine (CQ), a
cheap and well-tolerated drug, inhibits the growth of
dengue viruses in the laboratory with concentrations
achievable in the body. To measure the antiviral efficacy of
CQ in dengue, we conducted a study involving 307 adults
with suspected dengue. Patients received a 3-day oral
dosage of placebo or CQ early in their illness. Unfortu-
nately, we did not see an effect of CQ on the duration of
viral infection. We did, however, observe that CQ had a
modest anti-fever effect. In patients treated with CQ, we
observed a trend towards a lower incidence of dengue
hemorrhagic fever, a severe form of dengue. We did not
find any differences in the immune response that can
explain this trend. We also found more adverse events,
primarily vomiting, with CQ. This trial provides valuable
new information on how to perform trials of antiviral drugs
for dengue.
Figure 1. Participant flow in the randomized controlled trial of CQ vs. Placebo.
doi:10.1371/journal.pntd.0000785.g001
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placebo-controlled trial of adolescents and adults with dengue.
Materials and Methods
Study setting, participants and treatment allocation
We performed a randomized (allocation ratio 1:1), double blind,
placebo-controlled parallel-group study in 307 adults hospitalized
for suspected DENV infection. Study participants were recruited
from the Hospital for Tropical Diseases (HTD) in Ho Chi Minh
City, Vietnam. Patients were eligible if they were $15 yrs, had a
self-reported illness history of 72 hrs or less and were suspected of
having dengue. Patients were excluded if they were pregnant or
receiving therapy for other chronic disorders, had a history of
hypersensitivity to CQ, or written consent from either the patient
or a parent was not obtained. Physicians in the Hospital for
Tropical Diseases were responsible for enrolment. Patients were
randomly assigned to receive CQ (Mekophar Chemical-Pharma-
ceutical Joint-Stock Company, Ho Chi Minh City, Viet Nam) or
placebo. The regimen for CQ was 600mg base (46150mg tablets)
on enrolment to the study, then 600mg on day 2 and 300mg on
day 3 (following the World Health Organization recommended
treatment regimen for CQ susceptible P. vivax) [25]. Patients in the
placebo arm received the same regimen of tablets (identical color
and size). All treatment courses were contained in identical pre-
packed bottles that were randomly assigned to patients via a
computer-generated sequence of random numbers in blocks of 20
patients. A pharmacist generated the random sequence and was
the only person who knew the content of each bottle. All patients,
care providers and study investigators were blinded to treatment
assignments. Physicians in the Hospital for Tropical Diseases were
responsible for ensuring that the correct sequence of study codes,
and therefore the treatment allocation, was followed. The study
medication was given within 1 hr of a baseline blood sample being
collected. Clinical care, including other treatments such as
parenteral fluid therapy was at the discretion of the attending
physician and following hospital guidelines. Case classification was
according to 1997 WHO classification criteria and was applied to
each case after review of study notes [26]. The Scientific and
Ethical committee of the HTD and the Oxford Tropical Research
Ethical Committee approved the study protocol and all patients
gave written informed consent. The trial was registered with the
ISRCTN Register (ISRCTN38002730).
Investigations
Clinical and laboratory investigations. Clinical history
and examination findings were recorded daily into case record
forms. An ultrasound was performed in all patients within 24hrs of
Table 1. Baseline characteristics in the intention-to-treat population.
Variables CQ group (N=153) Placebo group (N=154)
N (%) or Median (interquartile range)
Age (years) 22 (18–27) 22 (19–28)
Male sex 104 (68.0%) 106 (68.8%)
Dengue confirmed 128 (83.7%) 129 (84.3%)
Viremic 124 (81.0%) 124 (80.6%)
Infecting serotype:
DENV-1 80 (64.5%) 67 (54.0%)
DENV-2 26 (21.0%) 27 (21.8%)
DENV-3 14 (11.3%) 27 (21.8%)
DENV-4 4 (3.2%) 3 (2.4%)
viraemia (log10 copies/mL of plasma):
All serotypes 9.0 (8.0–9.6)
a 8.5 (7.6–9.3)
DENV-1 9.2 (8.3–9.8) 8.9 (7.9–9.7)
DENV-2 8.3 (7.0–9.4)
a 7.7 (6.3–8.6)
DENV-3 8.3 (7.6–9.1) 8.2 (7.4–9.3)
DENV-4 7.7 (6.9–8.7) 7.7 (6.0–8.5)
Serological status:
Primary 20 (15.7%) 12 (9.3%)
Secondary 105 (82.7%) 110 (85.3%)
Ambiguous 2 (1.6%) 7 (5.4%)
NS1 ELISA positive 113 (73.9%)
b 110 (71.4%)
Febrile 150 (98.0%)
c 147 (95.5%)
c
Temperature (uC) 39.3 (38.7–40) 39.5 (38.8–40)
Time since illness onset (hrs) 49 (40–56) 48 (40–57)
Platelet count at enrolment 129,000 (95,000–168,000) 125,000 (91,000–167,000)
aBaseline viraemia value missing for 1 patient in the CQ arm.
bTwo patients NS1 negative at enrolment became positive later (both in the CQ arm).
cThree patients afebrile at enrolment later developed fever (1 in the CQ arm and 2 in the Placebo arm).
doi:10.1371/journal.pntd.0000785.t001
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admission (prior to study drug administration), then twice daily
(around 9am and 3pm) for a minimum of 5 days after starting
treatment (defined as study day 1) and again 10–14 days after
discharge from the hospital. Plasma, for use in diagnostic
investigations, was stored frozen in multiple aliquots at 280uC
until use. A complete blood count, including hematocrit (Hct) and
platelet measurements, was performed daily for all patients. Hct
measurements were performed more frequently if clinically
indicated. The extent of hemoconcentration during symptomatic
illness was determined by comparing the maximum Hct recorded
during hospitalization with either the value recorded at follow-up
when available or against a sex-matched population value.
Adverse events. Adverse events (AE) were defined as any
unfavorable and unintended abnormal laboratory finding,
symptom or disease that occurred during the course of the
study, regardless of whether it was considered to be related to the
intervention. AEs were classified as mild (grade 1), moderate
(grade 2), severe (Grade 3) and life-threatening (grade 4) according
to the Common Terminology Criteria for Adverse Events from
National Cancer Institute. The relatedness of the AEs to study
drug was investigated and graded as definitely, probably, possibly,
unlikely to be, or not related.
Dengue diagnostics. A diagnosis of ‘‘confirmed acute
dengue’’ was reached using previously described serological
methods and a diagnostic algorithm [27]. DENV viraemia in
plasma was measured using an internally controlled, serotype-
specific, real-time RT-PCR TaqMan assay that has been
described elsewhere [28]. RNA extraction was automated
(NucliSens easyMAG, BioMerieux, Marcy l’Etoile, France).
Results were expressed as cDNA equivalents per ml of plasma.
Sample measurements were only valid when there was a
detectable signal from the internal control amplicon and were
considered as positive if above the assay limit of detection defined
as the last dilution of standard that gave a specific signal. NS1 was
detected by using the NS1 Platelia assay from BioRad (Hercules,
CA) according to the manufacturer’s instructions.
Outcome assessment
Primary outcomes. The primary endpoints were the time
to resolution of viraemia and the time to resolution of NS1
antigenaemia. Time to resolution of viraemia was defined as the
time from the start of treatment until the first of two consecutive
plasma samples were RT-PCR negative. Time to resolution of
NS1 antigenaemia was defined as the time from the start of
treatment until the first of two consecutive plasma samples were
NS1 ELISA negative. Patients who did not reach viraemia or NS1
antigenaemia clearance were treated as censored at their last date
of viraemia or NS1 antigenaemia measurement.
Secondary endpoints. The fever clearance time (FCT) was
defined as the time from the start of treatment to the start of the
first 48 hour period during which axillary temperature remained
below 37.5uC. Other pre-defined secondary endpoints were- a)
the median nadir platelet count, b) the mean maximum %
hemoconcentration (calculated as (maximum hematocrit recorded
during the inpatient period)2(hematocrit at follow-up when avail-
able or a sex-matched population value)/(hematocrit at follow-up
when available or a sex-matched population value)6100), c) the
proportion of patients who were treated with intravenous fluid (the
decision was based in clinical signs and conducted according to
Hospital for Tropical Diseases protocols ; briefly, intravenous
fluids were given if the attending physician believed treatment was
necessary because of persistent vomiting, gastrointestinal bleeding,
hemoconcentration or hypotension), d) the proportion of patients
in each arm classified as having dengue hemorrhagic fever (DHF),
e) the proportion of patients in each arm with grade 3 or 4 adverse
events that were probably or definitely related to the intervention,
f) the proportion of patients in each arm with one or more episodes
of vomiting and g) the proportion of patients in each arm with
bleeding that required blood transfusion.
T cell and cytokine investigations
To determine the optimal time point for cytokine measurement,
levels of IL-1b, IL-6, IL-8, IL-10, IL-12p70, and TNF-a were
measured on serial plasma samples from 39 patients by using a
CBA Human Inflammatory Cytokines kit (Becton Dickinson, San
Jose, CA) according to the manufacturer’s instructions (except that
all samples were fixed in 4% paraformaldehyde before being
analyzed). Subsequently, a luminex-based Bio-Plex system (Bio-
Rad Laboratories, Hercules, CA) was used according to the
manufacturer’s instructions to measure simultaneous plasma levels
of IL-2, IL-4, IL-6, IL-8, IL-10, granulocyte macrophage colony
stimulating factor (GM-CSF), INF- c, and TNF-a in 1 plasma
sample from each patient. Flow-cytometric analysis of whole-blood
samples stained with fluorochrome-conjugated monoclonal
antibodies (CD3-Cy, CD4-PE-Cy7, CD8-PE, CD38-FITC,
HLA-DR-PerCP and Ki67FITC) was performed by use of a
FACScalibur flow cytometer (Becton Dickinson (BD)). Cell-surface
staining was routinely performed on 150mL of fresh whole blood.
All antibodies were purchased from BD. Whole-blood samples
from healthy volunteer subjects were used as group control.
Sample size calculation
Assuming a median time from enrolment to resolution of
viraemia or NS1 antigenaemia in the placebo group of 72 hours
and a reduction of this time by 24 hours due to CQ treatment
(corresponding to a hazard ratio of 0.67 assuming an exponential
distribution of the resolution times), we would need to observe
viraemia or NS1 antigenaemia resolution in 191 patients to show
such an effect with 80% power at the two-sided 5% significance
level. Assuming sufficient follow-up to observe viraemia or NS1
antigenaemia resolution in 90% of patients, we would need to
include at least 213 patients with confirmed dengue.
Statistical methods
The statistician was unblinded for the data analysis. Data stayed
blinded until the database was cleaned and locked ready for data
analysis. All statistical analyses were performed using Intercooled
STATA version 9.2 (StataCorp, TX). A two-sided p-value #0.05
was considered significant for all parameters. The intention-to-
treat (ITT) population was defined as all subjects who were
randomized regardless of whether or not they began the treatment
regimen. All laboratory confirmed dengue patients completing the
expected number of days of treatment who fulfilled the inclusion/
exclusion criteria of the protocol and who did not leave before the
end of the study drug course formed the per-protocol (PP)
population. Secondary endpoints (except the FCT) were compared
between the 2 groups and analyzed using the Kruskal-Wallis test
Figure 2. Time to fever clearance. Kaplan – Meier survival analysis of time to fever clearance by treatment group (CQ or placebo) and population;
A) Intention to treat population and B) Per Protocol population. Three patients afebrile at enrollment developed fever later (1 in the CQ arm and 2 in
the Placebo arm) and for the purposes of analysis were considered positive at the time of enrolment.
doi:10.1371/journal.pntd.0000785.g002
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variables. For the primary endpoints and the FCT, the null
hypothesis is that CQ has no effect on duration of DENV
viraemia, NS1 antigenaemia and fever. Survival analysis using the
Kaplan-Meier (KM) method and log-rank test was used for all
time-to-event outcomes. Cox regression was used to quantify the
difference in risk between treatment groups and to adjust for all
the following baseline variables: time since illness onset at enrol-
ment, serological status, serotype (DENV-1 vs other), viraemia and
temperature. Because these covariates were thought to influence
the time to resolution of viraemia, the time to resolution of NS1
antigenaemia and the FCT, all were retained in the final adjusted
models. The proportional hazards assumptions were checked
using a test based on Schoenfeld residuals.
Results
Baseline characteristics of enrolled patients
Between May 2007 and July 2008, 307 adults with suspected
dengue were randomized to CQ or placebo (Fig. 1). Of these 307
patients, 257 had laboratory confirmed dengue and 50 had no
evidence of recent or acute dengue. All patients recovered fully.
The baseline characteristics of the study population are summa-
rized in Table 1. Baseline characteristics were generally well-
balanced between the two groups except for baseline viraemia
which tended to be higher in the CQ group (median 9.04 vs 8.52
Log10 copies/mL) and the proportion of DENV3 infected
patients, which was lower in the CQ arm (11.3% CQ vs 21.8%
placebo).
Primary endpoints
DENV viraemia clearance times. There were 248 patients
viraemic at enrolment in the ITT population and 239 in the PP
population (Table 1). Viraemia clearance times were not
significantly different in the CQ arm compared to the placebo
arm for either the ITT or PP analysis (Fig. 2A and B) (ITT hazard
ratio (HR) 0.80, 95% CI 0.62–1.05, log rank test P=0.10 and PP
HR=0.80, 95% CI 0.61–1.05, log rank test P=0.11). Median
times to resolution of DENV viraemia were similar in the ITT and
PP population: ITT 77.5hrs and PP 78hrs (ITT inter-quartile
range (IQR) 53–100hrs and PP IQR 66–100.5hrs) for CQ
arm and both ITT and PP 71hrs (IQR ITT 48–94.5hrs and PP
48–95.5hrs) for Placebo arm. Adjusting for baseline covariates did
not alter these findings (ITT HR=0.95, 95% CI 0.72–1.26 and
PP HR=0.94, 95% CI 0.71–1.25). Of the 24 patients still qRT-
PCR positive at discharge (median discharge time for those
patients=5 days since enrolment) only 14 presented at follow-up
and none were qRT-PCR positive (median follow up time for
those patients=13 days after enrolment).
Time to negative NS1 antigenaemia. In the ITT
population, there were 223 (72.6%) patients NS1 positive at the
time of enrolment (plus 2 patients negative at enrolment but NS1
positive 24 and 42hrs later) (Table 1). Time to resolution of NS1
antigenaemia was not significantly different between CQ and
placebo arms (Fig. 3A) (HR=1.07, 95% CI 0.76–1.51, log rank
test P=0.70). Adjusting for baseline covariates did not alter these
findings (HR=1.18, 95% CI 0.82–1.68). Median times to
resolution of NS1 antigenaemia were 96hrs (IQR 65.5–115hrs)
in the CQ arm and 94.5hrs (48–120hrs) in the placebo arm. There
were 96 patients still NS1 ELISA positive at discharge. This
suggests that NS1 antigenaemia is relatively long lived. Moreover
17 patients (,27% of patients NS1 positive at discharge and with a
follow-up sample) were still NS1 positive at follow-up (time range:
10.7–14 days after enrolment).
In the PP population, there were 215 (87.0%) patients NS1
positive at the time of enrolment (plus 2 patients negative at
enrolment but NS1 positive 24 and 42hrs later) (Table 1). Time to
resolution of NS1 antigenaemia was not significantly different
between CQ and placebo arms (Fig. 3B) (HR=1.14, 95% CI
0.80–1.63, log rank test P=0.47). Adjusting for baseline covariates
did not alter these findings (HR=1.19, 95% CI 0.83–1.71).
Median times to resolution of NS1 antigenaemia were 96hrs (IQR
66–116hrs) and 96hrs (54–120hrs) respectively for CQ and
placebo arms.
Secondary endpoints
Fever clearance times. In the ITT population, there were
297 patients febrile at enrolment (plus 3 afebrile who developed
fever soon after) (Table 1). FCTs were significantly shorter in the
CQ arm compared to the placebo arm (HR=1.37, 95% CI 1.08–
1.74, log rank test P=0.01 but there was a trend that the hazards
were non-proportional p=0.07) (Fig. 4A). However, when
adjusted for baseline covariates, the rate of fever clearance
among patients who received CQ was not different from
patients who received placebo (HR=1.16, 95% CI 0.89–1.51,
P=0.28). Median FCTs were 69hrs (IQR 45–93hrs) and 75hrs
(IQR 36.5–99hrs) respectively for CQ and placebo arms.
There were 240 patients febrile at enrolment (plus 2 afebrile
who developed fever soon after) in the PP population (Table 1).
FCTs were not different between the 2 groups (HR=1.24, 95%
CI 0.96–1.60, log rank test P=0.10) (Fig. 4B). Adjusting for
baseline covariates did not alter these findings (HR=1.28, 95% CI
0.98–1.68, P=0.07). Median FCTs were 69hrs (IQR 45–93hrs)
and 76hrs (IQR 46–99hrs) respectively for CQ and placebo arms.
Platelet nadir and maximum hemoconcentration. The
median nadir platelet count was the same in the CQ and placebo
arms 45,000 (IQR 25,000–60,000) (Mann-Whitney p=0.61, PP
population). There were also no significant differences between the
two arms in the mean level of hemoconcentration detected (10.8%
(8.9–12.7) and 12.2% (10.3–14.1) for the CQ and placebo
respectively (Mann-Whitney p=0.27, per protocol).
DF vs. DHF in each arm. There was a trend, though not
significant (P=0.09), towards fewer patients with DHF in the CQ
arm (Table 2). There were 29 patients (23.2%) with DHF in the
CQ arm compared to 41 (33.6%) in the Placebo arm (odds ratio
0.60, 95% CI 0.34–1.04, P=0.07). As the infecting DENV
serotype might influence clinical severity, and at baseline the two
arms differed in the prevalence of each serotype, the analysis of the
effect of CQ on disease severity was also adjusted for serotype by
logistic regression, but this did not alter these findings.
Adverse events. Two patients in the CQ arm developed
severe adverse events (both grade 3) that were possibly related to
CQ. One patient with hematemesis was admitted to the ICU for 3
days, with stable vital signs. The 2
nd patient was anorexic and
vomiting with a narrow pulse pressure 100/80 mmHg) and was
admitted to the ICU for 3 days. There were no severe AEs in the
placebo arm. Significantly more adverse events occurred in the
CQ arm: 18 patients reported a total of 33 AEs versus 6 patients
with 8 AEs in the placebo arm (Fisher’s exact test P=0.01)
Figure 3. Time to resolution of viraemia. Kaplan – Meier survival analysis of time to resolution of plasma viraemia by treatment group (CQ or
placebo) and population; A) Intention to treat population and B) Per Protocol population.
doi:10.1371/journal.pntd.0000785.g003
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of all grade adverse events) (Table 2).
Number of patients requiring fluid and blood transfusion
Thirty two patients (21 in CQ arm and 11 in placebo arm)
required parenteral crystalloid fluid therapy during their hospital-
ization (for rehydration, and/or maintenance) but none required
blood transfusion (Table 2). There was no significant difference
between the 2 groups in the need for fluid therapy (p-value=0.11
in the PP population and 0.06 in the ITT population).
T cell activation in peripheral blood of study participants
Given the clinical experience of using CQ therapy in
inflammatory autoimmune disorders, we investigated whether
CQ was associated with a measurable attenuation of the T cell
response. To this end, the activation state of peripheral blood
CD3
+CD4
+ and CD3
+CD8
+ T cells was assessed in fresh whole-
blood at the time of enrolment, on illness day 6, and again at
follow-up in 172 consecutive patients enrolled in the study
between September 07 and June 08 (85 in CQ arm, 87 in
placebo arm), amongst whom there were 147 laboratory-
confirmed dengue patients. The activation markers used were
CD38, HLA-DR and Ki-67. As a reference, we also phenotyped T
cells in fresh whole blood from 9 healthy adult volunteers.
Strikingly, in dengue patients we observed a large population of
surface-activated (CD38
+ or HLA-DR
+) and proliferating (Ki-67
+)
CD8
+ T cells at early convalescence that were mostly absent at the
time of enrolment and follow-up (Fig. 5). There was no evidence
however of a significant difference in the proportion of activated T
cells in patients treated with CQ or placebo.
Plasma concentrations of cytokines/chemokines
To understand if CQ modulated the cytokine response to
DENV infection, plasma concentrations of IL-2, IL-4, IL-6, IL-8,
IL-10, GM-CSF, INF-c, and TNF-a were measured in plasma
from 234 laboratory-confirmed dengue patients (121 in CQ arm,
113 in placebo arm) 2 or 3 days after randomization (Fig. 6).
However, there was no significant difference in plasma concen-
trations of any of these cytokines between CQ or placebo treated
patients (Mann-Whitney P.0.1).
Discussion
There are no specific therapies for treating dengue. This
controlled trial was conducted to determine if CQ could reduce
the viral burden in dengue patients. We found no evidence that
CQ reduced the duration of viraemia or NS1 antigenaemia in
adult dengue patients, but did observe a modest anti-pyretic
activity of CQ in the intention to treat population, but not in
dengue laboratory-confirmed cases. CQ was associated with a
higher frequency of adverse events compared to placebo, but these
were generally mild. There was no evidence that CQ reduced the
magnitude of cytokine or T cell responses to DENV infection.
To our knowledge the only previous therapeutic trial of CQ for
an acute viral infection has been in a small number of patients with
Chikungunya virus infection [29], in which CQ had no impact on
either duration of febrile arthralgia or viraemia. Several possible
reasons could explain the lack of measurable activity in this study
of CQ against virological markers of DENV infection in vivo.
Although the Cmax of CQ inside cells approximates the IC50 value
of CQ against DENV in vitro, it is possible that CQ does not
achieve inhibitory concentrations inside the reticuloendothelial
cells where DENV replication is believed to occur [30].
Furthermore, it may not achieve the same pH modulation in vivo
that is postulated to explain its activity on cultured virus in vitro.
Alternative trial designs and protocols, such as increasing the
therapeutic dose, dosing patients earlier in their illness or
increasing the sample size substantially might increase the chances
of observing an in vivo effect by CQ on the duration of DENV
viraemia and NS1 antigenaemia. The importance of treating early
is highlighted by the fact that in this trial the median duration of
illness prior to treatment was relatively short (,48 hrs) and the
median viraemia clearance times after treatment were ,3.75 days
in the CQ arm and ,3 days in the placebo arm. Strikingly
however, the duration of NS1 antigenaemia was relatively long,
with as many as 92/243 (38%) of dengue patients still NS1 positive
at the time of discharge from hospital, although most of this
antigen is probably generated in the first few days of illness and its
prolonged clearance simply reflects its large, oligomeric structure
[31,32]. The time to resolution of NS1 antigenaemia may
therefore not be an optimal endpoint and an alternative approach
could have been to compare the proportion of patients that were
positive at a single post-therapy timepoint (e.g. study day 5).
Collectively, these data underscore that there is only a brief
therapeutic window of opportunity to improve upon the host’s
virus-eliminating immune response. Encouragingly however,
strategies to diagnose patients very early in their illness are
available in the form of NS1 rapid diagnostic tests [27,33,34,35]
and these could in principal guide rational treatment with an anti-
viral or other intervention as early as 24–48hrs into the illness
course. Of additional value, but not yet identified, would be early
prognostic markers of severe outcome, so that interventions can be
delivered to those patients at higher risk.
A CQ-mediated anti-pyretic effect equal to paracetamol has
been shown during treatment of uncomplicated P. falciparum
malaria [24,36,37]. This effect may be explained by CQ’s anti-
inflammatory properties, including CQ effects on TLR signaling
[38,39]. Fever during an infection is thought to be initiated by
virtually immediate cyclooxygenase-2, prostaglandin E2 (PGE2)
production, activation of hypothalamic PGE2 receptors and then
Figure 4. Time to negative NS1 antigenaemia. Kaplan – Meier survival analysis of time to resolution of NS1 antigenaemia by treatment group
(CQ or placebo) and population; A) Intention to treat population and B) Per Protocol population. Two patients NS1 negative at enrollment were later
positive (both in the CQ arm) and for the purposes of analysis were considered positive at the time of enrolment.
doi:10.1371/journal.pntd.0000785.g004
Table 2. Summary of secondary endpoints.
CQ N (%) Placebo N (%) P value
a
Intention to treat population 153 154
Patient with AE 18 (11.8%) 6 (3.9%) 0.01
Patient with vomiting 15 (9.8%) 6 (3.9%) 0.04
Patient requiring IV fluid 21 (13.7%) 11 (7.1%) 0.06
Per protocol population 125 122
Patient with AE 17 (13.6%) 5 (4.1%) 0.01
Patient with vomiting 14 (11.2%) 5 (4.1%) 0.05
Patient requiring IV fluid 19 (15.2%) 10 (8.2%) 0.11
DHF patient 29 (23.2%) 41 (33.6%) 0.09
aFisher’s exact test.
doi:10.1371/journal.pntd.0000785.t002
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that CQ mediates an anti-pyretic effect by altering the levels and
balance of these pyretic mediators during infection. Accordingly,
we found a small reduction in fever clearance median times
(,6 hrs) amongst CQ patients in the intention-to-treat patient
population, and whilst a similar trend was observed amongst the
dengue confirmed patients, it was not statistically significant. CQ
might be a better anti-pyretic in non-dengue patients in this study
because these patients had milder infections, albeit of unknown
origin.
Fewer patients receiving CQ developed DHF. The intriguing
possibility that CQ mediated an anti-disease effect, but not a
measurable anti-viral effect in this trial is plausible given the
literature on CQ as a pleotropic immune-modulatory drug. To
find support for this possibility we measured pro- and anti-
inflammatory plasma cytokine concentrations and T cell activation
markers in dengue patients. Of particular interest were vasodila-
tory and pyretic cytokines such as TNF-a that have been identified
as susceptible to CQ modulation [18,41] and important in the
pathogenesis of the dengue capillary leak syndrome [42].
Similarly, the magnitude of T cell activation has been postulated
to be associated with dengue severity [43]. Whilst robust T cell
activation and cellular proliferation was indeed present around the
time of defervescence, there was no evidence of a difference
between CQ and placebo arms for the cellular markers we
investigated nor in the cytokines that were measured. The absence
of a measurable impact by CQ on these elements of the host
response might suggest any trend towards less DHF in the CQ arm
is simply chance or reflects our inability to identify and measure
true immunological correlates of disease. Only further large trials,
with clinical endpoints, will determine if CQ has a disease
modulating effect.
Our study had several limitations. The study was hospital-
based and therefore the patient population, although presenting
early in their illness, may not reflect that seen in primary health
care settings where milder infections might be expected. The
study was performed in adults, who generally compensate well for
capillary permeability, and it’s plausible that different findings
might be observed in children, who in most endemic settings
carry much of the disease burden. We measured viraemia by
quantitative RT-PCR as a surrogate and well characterised
marker of infection though we recognise this is not that same as a
quantitative biological assay of infectious virus. Finally, we did
not formally conduct pharmacokinetic analysis of CQ in treated
patients and this could have aided the interpretation of the final
outcomes.
Figure 5. Surface phenotypes of CD4
+ and CD8
+ T cells in laboratory-confirmed dengue patients randomized to placebo or CQ. The
Box and Whisker plots show the median number and range (2.5–97.5 percentile) of percentages of surface-activated T cells in peripheral blood from
CQ (n=74) and Placebo (n=73) treated laboratory-confirmed dengue patients at different time points. The median illness day (range) for enrolment
samples was 2 (0–3) days, for hospital discharge was 6 (4–8) days and for follow-up was 15.5 (13–30) days. Shown are percentages of peripheral blood
CD4
+ T cells that were A) CD38
+HLA-DR
+, B) CD38
+Ki67
+, and C) Ki67
+ HLA-DR
+. Also shown are percentages of CD8
+ T cells that were, D) CD38
+,
HLA-DR
+, E) CD38
+Ki67
+, and F) Ki67
+ HLA-DR
+. The labels below the graphs indicate the time at which sample collection occurred.
doi:10.1371/journal.pntd.0000785.g005
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for dengue [44,45]. This study illuminated several important issues
in the design of anti-viral interventions trials. Most striking is the
rapid decline in the DENV viraemia beginning ,72hrs into the
illness, highlighting the fact that anti-viral interventions will likely
need to be delivered very early and aggressively, preferably guided
by cheap, sensitive and specific diagnostics. NS1 is a useful and
easily assayed biomarker of DENV infection and in the context of
a trial it conceivably provides a slightly different insight into virus
infection than is given by measurement of viral RNA in plasma. In
early phase trials, measurement of virological and clinical markers
at multiple time-points per day is strongly recommended given the
speed of viral clearance and evolution of disease. In later phase
trials, the choice of clinical endpoints will depend on the target
patient population and the setting. In children, single or
combination endpoints around dengue shock syndrome, the most
common life-threatening complication in children, should be
considered. In adults, other complications such as severe bleeding
may also be relevant.
In summary, this study suggests CQ has no measurable impact
on virological or immunological parameters of DENV infection in
young adults. We also found no convincing evidence that CQ
reduces the time to fever resolution in adults with dengue.
Interventions with either more potent anti-viral molecules and/or
immunomodulatory drugs are needed to improve clinical
outcomes for patients in endemic settings.
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